GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

27 Sep 2006 07:00

Omega Diagnostics Group PLC27 September 2006 Omega Diagnostics Group PLC 26-Sep-2006 Omega Diagnostics Group PLC (formerly Quintessentially English PLC) (the "Company") Interim Results The Company announces its interim results for the six month period to 30th June2006. These interim results do not include any results for Omega DiagnosticsLimited ("Omega"), the acquisition of which was announced on 24th August 2006and unanimously approved by shareholders at the EGM on 18th September 2006. Since the Company's Admission to AIM in March 2004 it has continued to evaluatea number of potential acquisitions and this has resulted in the purchase ofOmega. During the six months ended 30th June 2006, there was a turnover in respect ofthe Company (excluding Omega) of £Nil, and a loss after tax of £73,218, the bulkof which related to abort fees incurred on prospective acquisitions paid toadvisers undertaking due diligence. No Company directors received anyremuneration during the period and no dividend is recommended. The future Omega manufactures and distributes test kits for tropical and other diseases ona global basis, selling product through a strong distribution network in over100 countries and which it has been involved in for the past 19 years. Omega hasidentified a number of prospective and related acquisitions and intends to growin this way. Michael Gurner will be staying on as a non-executive director and Robert Coe andGraham Ashley have resigned following the EGM. David Evans has become Chairmanand Andrew Shepherd and Kieron Harbinson have joined the Board as ChiefExecutive and Finance Director respectively. For further information: Omega Diagnostics Group PLCMr Michael Gurner, 07768 231 731 Profit and Loss AccountFor the period 01/01/06 to 30/06/06 Note Period Ended 30/06 Period Ended 30/06 /2006 (unaudited) /2005 (unaudited) £ £ Turnover - -Administrative expenses (75,850) (60,633)Operating Loss (75,850) (60,633)Interest Receivable 2,674 4,382Interest Payable (42) (32)Loss on ordinary activities before taxation 1 (73,218) (56,283)Taxation - -Loss on ordinary activities after taxation (73,218) (56,283)Basic and diluted earnings per Ordinary share (pence) (0.66) (0.50)Dividends per share (pence) 0 0 Balance SheetAs at 30/06/06 Note 30/06/2006 30/06/2005 (unaudited) (unaudited) £ £ £ £ Fixed AssetsInvestments 2 2Current AssetsPrepayments 3,825 0Cash at bank in hand 124,820 198,277Current LiabilitiesCreditors: Amounts falling (80,122) (48,120)due within one yearNet current assets 48,523 150,157Total assets less current 48,525 150,159liabilitiesCalled up share capital 2 111,769 111,769Share premium 3 167,867 167,867Profit and loss account (231,111) (129,477)Equity shareholders funds 48,525 150,159Net assets per share (pence) 4 0.43p 1.34p Cash Flow Statement For the period from 01/01/06 to 30/06/06 Note Period Ended 30/06 Period Ended 30/06 /2006 (unaudited) /2005 (unaudited) £ £ Net cash inflow from operating activities (29,938) (28,677)Returns on investment and servicing of finance:Interest received 2,674 4,382Interest payable (42) (32)Decrease in cash (27,306) (24,327) Notes to the Interim Report 1. Loss on ordinary activities before taxation The loss for the period is representative of operational overheads incurred inthe period. 2. Called up share Capital The issued share capital compromises 11,176,865 ordinary shares of 1p each,consisting of 200 shares of 1p each issued as two £1 subscriber shares onincorporation and converted into 1p shares on 23rd February 2004, 6,666,665ordinary shares of 1p each issued on 24th February 2004 and 4,510,000 ordinaryshares of 1p each issued on 18th March 2004. 3. Share premium The share premium represents: £ Premium arising on issues of ordinary shares in the period ended 31/12/2004 213,731Expenses of shares issues in the period ending 31/12/2004 (45,864) At 30th June 2006 167,867 4. Net assets per share The calculation of net assets per share is based on the net assets at the end ofthe period of £48,525 and on the number of ordinary shares in issue (11,176,865)at 30th June 2006. 5. Preparation of Interim Report The interim financial information for the period from 1 January 2006 to 30thJune 2006 was approved by the directors on 26 September 2006. 6. Financial information The financial information in this statement does not constitute statutoryaccounts within the meaning of section 240 of the Companies Act 1985. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Oct 20197:00 amRNSTrading Update and Notice of Interim Results
15th Oct 20192:29 pmRNSHolding(s) in Company
14th Oct 20198:18 amRNSHolding(s) in Company
14th Oct 20197:00 amRNSHolding(s) in Company
11th Oct 20198:00 amRNSHolding(s) in Company
10th Oct 201910:30 amRNSResult of General Meeting
27th Sep 201910:00 amRNSNotice of AGM and posting of annual report
23rd Sep 20197:01 amRNSPlacing & Subscription, Notice of General Meeting
23rd Sep 20197:00 amRNSFinal Results
16th Sep 20197:00 amRNSUpdate on VISITECT® CD4 Advanced Disease
10th Sep 20197:00 amRNSPurchase Order for Chinese Food Detective® test
20th Aug 20197:00 amRNSFirst VISITECT® CD4 Advanced Disease Test Order
16th Aug 201911:00 amRNSRe. Results, Trading Update & Nigerian CD4 Order
8th Aug 20197:00 amRNSInvestor Briefing
6th Jun 20197:00 amRNSAnnouncement of Results
5th Jun 20191:37 pmRNSHolding(s) in Company
3rd Jun 20191:43 pmRNSHolding(s) in Company
22nd May 20197:00 amRNSSubscription to raise c.£635,000
17th Apr 20197:00 amRNSTrading Update
18th Mar 20197:00 amRNSCE-Mark for VISITECT® CD4 Advanced Disease test
6th Mar 20197:00 amRNSVISITECT® CD4 update
1st Mar 20197:00 amRNSBoard Appointment
29th Jan 20197:00 amRNSVISITECT® CD4 Advanced Disease test update
10th Dec 20189:00 amRNSDirectorate Change
3rd Dec 20187:00 amRNSInterim results
19th Oct 20184:27 pmRNSHolding(s) in Company
10th Oct 20187:00 amRNSTrading Update and Notice of Interim Results
8th Oct 20182:38 pmRNSHolding(s) in Company
27th Sep 20187:00 amRNSAllergy CE-Mark and first Purchase Order
14th Sep 201811:25 amRNSResult of AGM
10th Sep 20188:56 amRNSHolding(s) in Company
6th Aug 20187:01 amRNSFinal Results
6th Aug 20187:00 amRNSVISITECT® CD4 Advanced Disease Development Update
30th Jul 20185:29 pmRNSHolding(s) in Company
18th Jul 20187:00 amRNSVISITECT® CD4 commercialisation update
12th Jul 20187:00 amRNSInvestor results presentation
2nd Jul 20187:00 amRNSNotice of Results
28th Jun 20187:00 amRNSDisposal of infectious disease business
21st May 20187:00 amRNSVISITECT CD4 development update
8th May 20187:00 amRNSAllersys? CE-Mark
2nd May 20187:41 amRNSClosure of Omega Diagnostics GmbH
24th Apr 20185:04 pmRNSPDMR Dealing
24th Apr 20187:00 amRNSHolding(s) in Company
23rd Apr 20183:50 pmRNSHolding(s) in Company
23rd Apr 20182:24 pmRNSDirector/PDMR Shareholding
23rd Apr 20182:22 pmRNSHolding(s) in Company
23rd Apr 20189:31 amRNSDirector/PDMR Shareholding
20th Apr 20187:00 amRNSAllersys Distribution Agreement
19th Apr 201811:45 amRNSInvestor Evening
10th Apr 20184:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.